无色素性/低色素性原发性皮肤黑色素瘤的分子机制
该研究对34例新鲜冷冻原发性皮肤黑色素瘤进行全外显子测序,按色素含量分级,分析16个与白化病/色素减退相关基因的胚系和体细胞变异。发现70%(7/10)无色素性/低色素性黑色素瘤(AHM)患者携带AHM相关胚系变异,而色素性黑色素瘤(PM)仅8%(2/24);在8例携带色素基因变异的AHM中,50%(4/8)存在相应基因区域的杂合性缺失(LOH)。结论提示AHM的分子机制可能为携带白化病/色素减退等位基因后肿瘤发生相应基因LOH。
要点
- AHM患者中AHM相关胚系变异频率高(70% vs PM 8%),提示遗传易感性。
- AHM肿瘤中常见色素基因区域LOH(50%),支持「二次打击」机制。
- 对无色素性黑色素瘤应警惕其遗传背景,辅助早期诊断。
核心结论
- AHM的发生可能源于携带白化病/色素减退等位基因,随后肿瘤中相应基因发生LOH。
研究设计与样本
- 对34例新鲜冷冻原发性皮肤黑色素瘤进行全外显子测序,按色素含量分级,分析16个色素相关基因的胚系和体细胞变异;其中30例曾分析拷贝数变异(CNA)。
主要发现
- AHM患者中AHM相关胚系变异富集于70%(7/10),PM患者为8%(2/24)。
- 在8例携带色素基因变异的AHM中,50%(4/8)存在包含对应基因区域的LOH,25%(2/8)存在两个AHM相关基因染色体区域的LOH。
临床怎么用
- 对于无色素性/低色素性黑色素瘤,可考虑评估胚系色素基因变异以辅助遗传咨询和早期识别。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Approximately 2-20% of cutaneous melanomas (CMs) are diagnosed as amelanotic/hypopigmented melanoma (AHM) and represent a challenge for early diagnosis. OBJECTIVES: To investigate loss-of-function mutations in key pigmentation genes in matched germline and AHM, as well as pigmented melanoma (PM), tumour DNA samples. METHODS: Analysis of clinical and histopathological characteristics - together with whole-exome sequencing data of 34 fresh frozen primary CMs, graded according to the amount of pigmentation present - was performed. Together with germline and somatic variant analysis, 30 samples had previously been analysed for copy number aberration (CNA) changes. This study focused on germline and somatic variants in the coding region of 16 genes known to be associated with albinism/hypopigmentation or variation in human pigmentation in all samples. Chromosomal regions encompassing these 16 genes were examined for DNA copy loss or gain. RESULTS: The finding that red hair-related MC1R and TYR R402Q loss-of-activity gene variant alleles and genotypes are associated with AHM was confirmed. Germline AHM-related gene variants were enriched in 70% (n = 7/10) of patients with AHM vs. 8% (n = 2/24) of those with PM. This surprisingly high frequency of rare germline variants in people with AHM constitutes the 'first hit' and confirms that those with AHM are more likely to be albinism allele carriers than individuals with PM. Next, in CNA analysis of each tumour sample, 50% (n = 4/8) of AHM samples with a pigmentation gene variant had loss of heterozygosity (LOH) in the region containing the corresponding gene and 25% (n = 2/8) had LOH in chromosomal regions of two AHM-related genes. CONCLUSIONS: This study proposes that the likely molecular mechanism for the development of amelanogenesis in AHM is carriage of an albinism/hypopigmentation allele followed by LOH of the corresponding gene in the tumour. Melanoma is a form of skin cancer. Up to 20% of melanomas are flesh-coloured tumours. Other melanomas can be coloured or ‘pigmented’. These differences present a challenge when trying to diagnose melanoma early. A type of flesh-coloured melanoma called ‘amelanotic/hypomelanotic’ melanoma (or ‘AHM’ for short) often develops with sun damage and in older people. The loss of colour, or ‘pigment’, in AHM is caused by a decrease in the amount of a substance called melanin produced in the tumour cells. We looked at possible genetic differences between AHM and pigmented melanoma. We examined changes in key genes associated with decreases in skin colouring or gene mutations that cause albinism (where no melanin is produced). We found variants in genes that cause albinism or reduced pigmentation in 7 of 10 people with AHM. Only 2 of 24 people with pigmented melanoma had these genetic variants. Overall, the high frequency of gene variants in people with AHM, together with a loss of gene function in the tumour, supports the idea that some people could be predisposed to getting AHM. This provides an explanation for the loss of melanin in AHM tumours.
引用
- Sturm RA, Smit DJ, Duffy DL, et al. Uncovering the molecular mechanisms of amelanotic/hypopigmented primary cutaneous melanoma. Br J Dermatol. 2024. PMID: 39166481. doi:10.1093/bjd/ljae336
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。